Chris Tame

Company: Celeris Therapeutics

Job title: Head of drug discovery

Seminars:

The Application of Computational Structural Biology Approaches to Support the Rational Design of Degraders 11:15 am

An introduction to current state-of-the-art methods for ternary complex modelling Bayesian Optimisation and Physics-based approaches developed by CelerisTx Generative AI for bespoke linker design Prospective and Retrospective validation of the CelerisTx ternary complex prediction pipelineRead more

day: Day 1 Track A AM

Panel Discussion: Can Computational Approaches Deliver on the Promise of More Efficient & Accurate Degrader Discovery & Development? 11:45 am

What is limiting AI/ML from accelerating TPD development? “Lots of data is needed” – how much? And how do we get there? Can we make the data available more amenable? What can computational methods currently deliver? What will happen to traditional approaches like docking?Read more

day: Day 2 Track A AM

TPD of the Future: Introducing Highly Sophisticated AI/ML Tools & Computational Techniques to Accelerate your Degrader Discovery & Development Programmes 2:30 pm

With the arrival of AI and Machine Learning (ML), a new age for TPD discovery and development is emerging. AI is enabling developers to make predictions on structures, conformational changes, and in turn, make educated decisions on what compounds to advance. We’ll explore how academia are using computational methods to expedite research, how ML is…Read more

day: Pre-Conference Workshop Day